SiteOne Therapeutics

SiteOne Therapeutics, located in San Francisco, is developing novel therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Our lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

Focus area
Neuroscience
Graduation date
10/05/2017
Commencement date
11/01/2013